Procter & Gamble Health Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Excellent return on equity (ROE 61.6%)
- Attractively valued vs sector (P/E 30.6x vs industry 54.7x)
- Virtually debt-free
- Regular dividends — yield 2.6%
Concerns
- High premium to book value (P/B 16.2x)
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,899 | ₹4.6L Cr | 36.1 | 5.46 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,100 | ₹2.4L Cr | 81.1 | 14.42 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,857 | ₹1.8L Cr | 82.8 | 19.58 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,650 | ₹1.2L Cr | 59.1 | 13.13 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,385 | ₹1.1L Cr | 31.3 | 3.25 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,120 | ₹1.1L Cr | 23 | 4.16 | 21.2 | 21.1 | 0.38 |
| LAURUSLABS Laurus Labs Limited | ₹1,840 | ₹99K Cr | 90.9 | 18.74 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
PGHL · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% | 51.82% |
| FII | 7.60% | 6.24% | 6.39% | 6.61% | 7.01% | 6.86% |
| DII | 12.66% | 13.72% | 14.56% | 14.84% | 14.71% | 14.21% |
| Public | 27.92% | 28.22% | 27.24% | 26.74% | 26.47% | 27.11% |
Corporate Events
Dividend - Rs 45 Per Share
Dividend - Rs 45 Per Share
To consider and approve the financial results for the quarter ended Jun 30, 2026
Interim Dividend - Rs 110 Per Share & Special Dividend Rs 50 Per Share
Dividend - Rs 45 Per Share
Interim Dividend - Rs 80 Per Share
Annual General Meeting/Dividend - Rs 60 Per Share
Interim Dividend - Rs 50 Per Share & Special Dividend Rs 150 Per Share
Annual General Meeting/Dividend - Rs 50 Per Share
Latest News
All newsP&G Health reports Q1 FY27 earnings
*P&G Health reports Q1 FY27 earnings.* The company released its financial results for the quarter ended June 30, 2026. Key metrics include **revenue of ₹** and **net profit of ₹**, reflecting growth trends in the healthcare FMCG segment. Traders will assess margins and guidance for near-term trading cues. 📊 *STOCKS:* $PGHL | 🏢 *SECTOR:* FMCG | #HIGHIMPACT #Earnings
P&G Health reports Q1 FY27 unaudited results
*P&G Health reports Q1 FY27 unaudited results*. The company announced its unaudited financial performance for the quarter ended June 30, 2026. Key figures include revenue of **₹218.4 crore** and net profit of **₹32.1 crore**. Results reflect steady performance in consumer healthcare segment. 📊 *STOCKS:* $PGHL | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Earnings
P&G Health informs exchange of investor presentation
*P&G Health informs exchange of investor presentation.* The company has shared details of an upcoming investor presentation as part of routine corporate disclosures. Such events are standard and typically used to update stakeholders on business performance and strategy. No immediate financial or operational developments were announced. 📊 *STOCKS:* PGHL | 🏢 *SECTOR:* Pharma | #LOWIMPACT #InvestorPresentation